AVP and neoplasm: Elevated levels of the three circulating vasoactive peptides—Mid-Regional Pro-Adrenomedullin, Mid-Regional Pro-Atrial Natriuretic Peptide and C-terminal-prepro-vasopressin (copeptin)—in CRC patients who received bevacizumab therapy are associated with an enhancement in progression time, indicating a potential association between the tumor vascularization and the patient’s circulatory system [17].